Ultragenyx Pharmaceutical Inc.

Historical 13F Holders

Symbol
RARE
CUSIP
90400D108
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 90400D108 since 12/18/2024, largest first.

Filer % of Class Filed
Vanguard Portfolio Management LLC 13G/A 8.6% 10/30/2026
Event 9/30/2026
BlackRock, Inc. 13G/A 8.3% 7/30/2026
Event 6/30/2026
RTW Investments, LP 13G
7.9% 8/14/2026
Event 6/30/2026
State Street Corp 13G
7.6% 11/10/2026
Event 9/30/2026
Madison Avenue Partners, LP 13G
6.4% 10/20/2026
Event 10/13/2026
Vanguard Capital Management LLC 13G 5.1% 7/31/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Sands Capital Management, LLC 13G/A
4.7% 2/12/2025
Event 12/31/2024
FMR LLC 13G/A
3.5% 2/5/2026
Event 12/31/2025
Wellington Management Group LLP 13G/A
2.7% 2/10/2025
Event 12/31/2024
AQR Capital Management, LLC 13G/A
0.6% 11/13/2026
Event 9/30/2026
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 275 105 M $1.58B
2026 Q2 318 107 M $3.55B
2026 Q1 301 98.2 M $2.05B
2025 Q4 299 93.9 M $2.16B
2025 Q3 314 96.6 M $2.91B
2025 Q2 318 94.1 M $3.42B
2025 Q1 308 89.8 M $3.25B
2024 Q4 322 87.5 M $3.68B
2024 Q3 308 86.9 M $4.82B
2024 Q2 275 88.2 M $3.63B
2024 Q1 275 79.9 M $3.73B
2023 Q4 241 80.4 M $3.84B
2023 Q3 224 70.6 M $2.52B
2023 Q2 245 69.5 M $3.21B
2023 Q1 232 68.7 M $2.76B
2022 Q4 231 68.1 M $3.15B
2022 Q3 237 67.9 M $2.81B
2022 Q2 228 67.6 M $4.03B
2022 Q1 242 67.3 M $4.87B
2021 Q4 238 67.8 M $5.70B
2021 Q3 224 66.7 M $6.01B
2021 Q2 243 65.5 M $6.24B
2021 Q1 262 67.9 M $7.73B
2020 Q4 260 67.7 M $9.37B
2020 Q3 209 63.2 M $5.20B
2020 Q2 196 63.2 M $4.94B
2020 Q1 178 60.2 M $2.67B
2019 Q4 175 58.3 M $2.49B
2019 Q3 175 58.7 M $2.51B
2019 Q2 172 58.9 M $3.74B
2019 Q1 182 58.4 M $4.05B
2018 Q4 167 50.6 M $2.20B
2018 Q3 179 50.0 M $3.82B
2018 Q2 160 49.1 M $3.78B
2018 Q1 166 48.9 M $2.50B
2017 Q4 165 43.2 M $2.01B
2017 Q3 156 40.6 M $2.16B
2017 Q2 163 41.5 M $2.57B
2017 Q1 170 40.9 M $2.77B
2016 Q4 178 41.8 M $2.94B
2016 Q3 177 39.5 M $2.80B
2016 Q2 165 37.0 M $1.81B
2016 Q1 165 37.4 M $2.37B
2015 Q4 173 35.9 M $4.03B
2015 Q3 162 35.4 M $3.46B
2015 Q2 152 32.5 M $3.33B
2015 Q1 127 31.6 M $1.96B
2014 Q4 101 28.0 M $1.23B
2014 Q3 102 26.5 M $1.50B
2014 Q2 82 20.2 M $816M
2014 Q1 77 18.9 M $815M